Jeroen Musch

The PRRT Treatment Center Rotterdam is part of the Nuclear Medicine Department. Patients with neuroendocrine tumors (NETs) are treated with PRRT (peptide receptor radionuclide therapy) in this center. Patients referred for PRRT treatment should meet these indications and the following criteria.

Important Inclusion Criteria

  • Inoperable or metastasized NETs
  • Pathology (cytology/histology) proven NET (usually grade 1 or 2)
  • Sufficient uptake/accumulation of radiotracer in the tumors on the OctreoScan
  • Serum creatinine < 150 umol/l and creatinine clearance (as determined by 2 x 24 hrs urine collections) >50 ml/min.
  • Hemoglobin ≥ 5.5 mmol/l; Leucocytes ≥ 2*109/l; Thrombocytes ≥ 100 * 109 /l
  • Total bilirubin ≤ 3 x upper limit of normal (ULN)
  • Albumin ≥ 30 g/l (or albumin < 30 g/l and normal prothrombin time)
  • Recent CT/MRI scan (not older than 3 months), preferably with measurable lesions
  • Self-sufficiency of the patient
  • Life expectancy longer than 3 months
  • Karnofsky Performance Score ≥60

Before the therapy starts, you need to stop taking certain medication.

Overview PRRT Steps

For a visual overview of the various steps before, during and after treatment, view the following schematic representations:


Go to the page with required information needed for treatment.
Or go directly to the contact page for physicians.